explore -WSS

explore

author：explore 2025-09-29 22:54:04 - browse：6

illustration of one blue dna strand — Adobe

The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Biogen nominates mother of director’s child to replace him on board

WSS

Xenotransplantation trials will require adjusting expectations, experts say

Friends ask where James Watson's attitudes about race came from

Eli Lilly’s Mounjaro succeeds in second weight

Police still searching for prisoner who escaped from NYC hospital

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Sea level rise could wash away turtle breeding grounds around the world, researchers say

leisure time

explore

explore

Malaria cases in Florida and Texas: Here’s what you need to know

Police still searching for prisoner who escaped from NYC hospital

Peter Hotez and the public health issue of online harassment

Mom launches Girl Scout troop for LGBTQ youth in Texas

Wildfire smoke exposes gaps in outdoor worker protections

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Moonlake's readout produced a cash windfall. Risks remain

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

In Memoriam: Notable people who died in 2023

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

hotspot

Timeline: Key moments in fight for gay rights

Drastic changes should bring profitability, startup health insurers say

Wegovy’s successful heart trial raises vital question about weight loss

FDA panel issues narrow recommendation for Covid vaccine booster doses

Friends ask where James Watson's attitudes about race came from

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

hotspot

hotspot

leisure time

focus